-
公开(公告)号：WO2020013693A1
公开(公告)日：2020-01-16
申请号：PCT/NL2019/050432
申请日：2019-07-11
Applicant: STICHTING VUMC
Inventor： NIEUWENHUIJZEN, Jacobus Adrianus , STEENBERGEN, Renske Daniëla Maria , BOSSCHIETER, Judith
IPC: C12Q1/6886
Abstract: The invention relates to methods for detecting the presence of, or risk at, bladder cancer using novel DNA methylation markers for bladder cancer and to kits of parts useful in such methods.
-
32.发明申请
公开(公告)号：WO2019220369A3
公开(公告)日：2019-11-21
申请号：PCT/IB2019/054034
申请日：2019-05-15
Applicant: JANSSEN BIOTECH, INC. , STICHTING VUMC
Inventor： ADAMS, Homer , GAUDET, Francois , FRERICHS, Kris , VAN DE DONK, Niels , VERLEIJ, Christie C.P.M.
Abstract: The disclosure provides methods of treating a cancer and/or killing tumor cells in a subject, comprising administering a therapeutically effective amount of an anti-CD38 antibody and a T cell redirecting therapeutic to the subject to treat the cancer. The disclosure provides a method of enhancing efficacy of a T cell redirecting therapeutic in a subject having a cancer, comprising administering to the subject an anti-CD38 antibody. The disclosure also provides a method of treating a multiple myeloma in a subject, comprising administering a therapeutically effective amount of a BCMAxCDS bispecific antibody and an anti-CD38 antibody to the subject to treat the multiple myeloma. The disclosure also provides a pharmaceutical combination comprising a GPRC5DxCD3 bispecific antibody. The disclosure also provides a kit comprising a pharmaceutical composition comprising a BCMAxCD3 bispecific antibody and an anti-CD38 antibody.
-
公开(公告)号：WO2018016943A1
公开(公告)日：2018-01-25
申请号：PCT/NL2017/050446
申请日：2017-07-04
Applicant: STICHTING VUMC , TEMMERMAN, Olivier Paul Pieter
Inventor： TEMMERMAN, Olivier Paul Pieter , PAALMAN, Micha Ilan
Abstract: Surgical instrument (1) for use on a patient's bone, com-prising a support rod or bar (2), and a breaking tool (3) provided at an extremity (4) of the support rod or bar (2), which breaking tool (3) comprises a nose (5} and a knife or chisel (6), wherein between the nose (5) and the knife or chisel (6) a room (7) is provided which is arranged to receive material that is to be removed from the bone, wherein the knife or chisel (6) has at least two surfaces (8) facing the nose (5), which surfaces (8) merge into a joint crossing line (9) substantially dividing the knife or chisel (6) into two parts on opposite sides of the crossing line (9), so as to provide a splitting operability to the knife or chisel (6).
Abstract translation: 用于患者骨上的手术器械（1）包括支撑杆或支撑杆（2）以及设置在支撑杆（4）的末端（4）处的破坏工具（3） （5）和刀或凿子（6）之间设有房间（7），所述房间（7）设置在所述房间 布置成接收将要从骨中移除的材料，其中刀或凿子6具有面向鼻部5的至少两个表面8，所述表面8合并成交叉线9 ）将刀或凿（6）基本上在交叉线（9）的相对侧上分成两部分，以便为刀或凿子（6）提供分开操作性。
-
公开(公告)号：WO2023281111A1
公开(公告)日：2023-01-12
申请号：PCT/EP2022/069203
申请日：2022-07-08
Applicant: CAMBRIDGE ENTERPRISE LIMITED , STICHTING VUMC
Inventor： BRINDLE, Kevin , MAIR, Richard , MOULIÈRE, Florent , ROSENFELD, Nitzan , SMITH, Christopher G.
Abstract: The present invention provides a computer-implemented method for analysing a urine sample from a subject. The method comprises providing the value of one or more cell-free DNA fragment size metrics for said sample, and determining whether the sample has a high or low likelihood of being from a brain cancer patient by providing said values of said cell-free DNA fragment size metrics as input to a machine learning model. The machine learning model is trained to classify sample data into one of at least two classes, the at least two classes comprising a first class having a high likelihood of being from a brain cancer patient and a second class having a low likelihood of being from a brain cancer patient. Methods for diagnosing or screening for brain cancer, detecting recurrence or residual disease, providing a prognosis or selecting a treatment for brain cancer are also described.
-
公开(公告)号：WO2021015619A1
公开(公告)日：2021-01-28
申请号：PCT/NL2020/050482
申请日：2020-07-23
Applicant: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS , STICHTING VUMC
Inventor： KOMÓR, Malgorzata Anna , PINTO MORAIS DE CARVALHO, Beatriz , FIJNEMAN, Remondus Johannes Adriaan , JIMENEZ, Cornelia Ramona , MEIJER, Gerrit Albert , DE WIT, Meike
IPC: G01N33/574
Abstract: The invention relates to methods for typing an individual suffering from a colorectal lesion, or suspected of suffering therefrom, based on a set of biomarkers. The invention further relates to methods of assigning treatment to an individual having a high risk colorectal adenoma, and to a kit comprising reagents for directly or indirectly determining a level of expression of the biomarkers.
-
Patent Agency Ranking36.发明申请
公开(公告)号：WO2019022605A1
公开(公告)日：2019-01-31
申请号：PCT/NL2018/050520
申请日：2018-07-25
Applicant: STICHTING VUMC
IPC: C12Q1/6886 , C12Q1/70
Abstract: The invention relates to the field of cancer prevention and medical diagnostics; and is concerned with a molecular diagnostic assay for cancers, especially human papillomavirus (HPV)-induced invasive cancers and high- grade precursor lesions thereof, such as invasive cervical cancer and premalignant cervical lesions. In particular, the present invention relates to the use of HPV-induced cancer specific miRNA reference genes miR-423, miR-30b, RNU24 and RNU43 to use microRNA (miR)-9, -15b,-20a,- 28, -31, -93, -100,- 125b, -149, -203, -222, -375 and let-7b-5p gene products as markers for hrHPV-induced invasive cancers, and their premalignant lesions with invasive potential.
-
37.发明申请
公开(公告)号：WO2017183978A1
公开(公告)日：2017-10-26
申请号：PCT/NL2017/050254
申请日：2017-04-21
Applicant: STICHTING VUMC
Inventor： PAULUS, Walter Joseph
IPC: A61K38/17 , A61K31/121 , A61P9/00
Abstract: The invention relates to the treatment of diastolic dysfunction in a subject, and relates in particular to compositions for use and methods in treating diastolic dysfunction. In one aspect the invention provides a composition for use comprising a therapeutically effective amount of a substance which increases the level and/or activity of a crystalline protein in cardiomyocytes of the subject. In particular the composition for use according to the invention comprises a therapeutically effective amount of the alpha B crystalline protein. It was found that the composition for use is capable of treating diastolic dysfunction and diastolic heart disease in subjects with failing hearts that have a higher cardiomyocyte stiffness than controls. Particularly, addition of alpha B crystalline reduced the higher stiffness of failing cardiomyocytes to the level observed in control cardiomyocytes.
Abstract translation: 本发明涉及治疗受试者的舒张功能障碍，并且具体涉及用于治疗舒张功能障碍的组合物和方法。 在一个方面，本发明提供了一种使用的组合物，其包含治疗有效量的物质，所述物质能够提高受试者心肌细胞中结晶蛋白的水平和/或活性。 具体而言，根据本发明使用的组合物包含治疗有效量的αB结晶蛋白。 发现使用的组合物能够治疗具有比对照更高的心肌细胞僵硬的衰竭心脏的受试者的舒张功能障碍和舒张性心脏病。 特别地，添加αB晶体使衰退的心肌细胞的更高硬度降低至在对照心肌细胞中观察到的水平。
-
公开(公告)号：PH12020551932A1
公开(公告)日：2021-06-21
申请号：PH12020551932
申请日：2020-11-13
Applicant: JANSSEN BIOTECH INC , STICHTING VUMC
Inventor： ADAMS HOMER , GAUDET FRANCOIS , FRERICHS KRIS , VAN DE DONK NIELS , VERKLEIJ CHRISTIE
IPC: A61K39/00 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30
Abstract: The present application relates to bispecific antibodies, either BCMA*CD3 or GRRC5D*CD3. The bispecific antibodies are to be used in the treatment of refractory cancers, especially after a previous treatment with an anti CD38-antibody.
-
公开(公告)号：CA3112513A1
公开(公告)日：2020-01-16
申请号：CA3112513
申请日：2019-07-11
Applicant: STICHTING VUMC
IPC: C12Q1/6886
Abstract: The invention relates to methods for detecting the presence of, or risk at, bladder cancer using novel DNA methylation markers for bladder cancer and to kits of parts useful in such methods.
-
公开(公告)号：ES2622112T3
公开(公告)日：2017-07-05
申请号：ES11731142
申请日：2011-05-02
Applicant: STICHTING VUMC
Inventor： VAN NIEUW AMERONGEN GEERTEN P , VONK NOORDEGRAAF ANTON , AMAN JURJAN , VAN HINSBERGH VICTOR W M
IPC: C12N15/113 , A61K31/506 , A61K31/713 , C07K16/18
Abstract: Un inhibidor de la función del gen relacionado con Abl (ARG) para usar en el tratamiento de un individuo que padece o está en riesgo de padecer edema inflamatorio, en donde dicho inhibidor se selecciona de: a) un inhibidor de la actividad tirosina quinasa de la proteína codificada por dicho gen relacionado con Abl (ARG), seleccionado entre nilotinib o una sal farmacéuticamente aceptable del mismo, dasatinib o una sal farmacéuticamente aceptable del mismo, e imatinib o una sal farmacéuticamente aceptable del mismo; b) un anticuerpo anti-ARG que se une a ARG e inhibe su función; y c) una molécula de ácido nucleico que provoca la degradación de ARG o inhibe la función, la transcripción o traducción de ARG.
-
-
-
-
-
-
-
-
-
Search Results
131
records
(took 0.023 seconds)
